EU project on intelligent materials to regenerate bone tissue

More than half a million Europeans suffer from disorders in or serious defects of some part of their bone structure. So, graft or implant operations needed to repair the damage depend decisively on the materials used. The Nanobiocom project, funded under the EU's Sixth Framework Programme (FP6), is working on the regeneration and repair of bone tissue. Its aim is to come up with a substitute for bone tissue that can repair the bone and regenerate it in such a way that it will be able to carry out similar functions to those in its natural state.

In the case of significant deterioration of the bone, it may be necessary for the implant to provide both functional and physiological properties of the damaged item. In such circumstances, the bone implants have to comply with certain requisites capable of contributing to a reconstruction of the deteriorated bone tissue in the most efficient and least harmful way possible, without any serious repercussions. Another requirement involves the carrying out of the mechanical functions of the damaged bone while the desired regeneration takes place.

In addition, the solutions have to be capable of remedying particularly serious damage, such as those due to congenital deficiencies, degenerative illnesses, cancerous disorders and other damage caused by accidents. The implants required for this type of solutions are more complex and sophisticated than the small implants known until now.

So the Nanobiocom project will seek to develop a support (scaffold) made out of a compound material that is 'intelligent', proactive, and capable of repairing and regenerating bone tissue. For this purpose, it has to be bioactive, capable of acting on the tissue-generating system and its corresponding genes, as well as responding correctly to the physiological and biological changes, both internal and external, of that system.

It is also necessary for its size and shape characteristics, as well as its mechanical functions, to correspond with those of healthy bones.

The specific tasks of the three-year project are now on fine tuning the intelligent material, based on nanoparticles and of a biodegradable nature. Also in the pipeline is the development of the cell culture in three dimensions, as well as ensuring the biocompatibility of the material.

Ultimately, the scientists involved in the frontier research project hope it will open new doors in the development of nanobiotechnology.

For more information, please visit:
http://nanobiocom.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...